Medshine Discovery Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Zhuhai United Laboratories Co., Ltd.

Other

Sichuan University

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Guangdong Raynovent Biotech Co., Ltd.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Genfleet Therapeutics (shanghai) Inc.

Shijiazhuang Sagacity New Drug Development Company, Ltd.

Luoxin Pharmaceutical (shanghai) Co., Ltd.

Hubei Bio-pharmaceutical Industrial Technological Institute Inc.

Harbin Zhenbao Pharmaceutical Co., Ltd.

Wuxi Fortune Pharmaceutical Co., Ltd

Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

Guoping Hu

Jian Li

Shuhui Chen

Charles Z Ding

Lihong Hu

Peng Li

Guibai Liang

Haiying He

Fei Sun

Kevin X Chen

Wenyuan Qian

Zhi Luo

Zhengxia Chen

Cheng Xie

Changqing Wei

Chunli Shen

Weiwei Mao

Xiaolin Li

Zhaobing Xu

Hao Wu

Fang Liu

Yong Wang

Yunfu Luo

Chengde Wu

Chundao Yang

Chaofeng Long

Xiaoxin Chen

Zhuowei Liu

Dahai Wang

Shilan Liu

Meibi Dai

Maoyi Lei

Zhaoguo Chen

Jianyu Lu

Xiongbin Xu

Xiaobing Yan

Xiaofei Wang

Yanxin Yu

Yikai Wang

Xuejian Zheng

Yaxian Cai

Xing Liu

Wei Huang

Fei Wang

Xiquan Zhang

Kai Zhou

Ling Yang

Hongjiang Xu

Tie-Lin Wang

Lingyun Wu

Tao Feng

Yuquan Wei

Kun Peng Wang

Yong Xu

Jun Zhao

Ling Liu

Yi Zhang

Zhifei Fu

Lele Zhao

Xile Liu

Lu Huang

Ning Zhao

Xuehai Wang

Boyu Hu

Lifang Wu

Zhe Cai

Ronghua Tu

Jian Wei Li

Xiawei Wei

Xinde Chen

Linghui Wu

Jiaqiang Dong

Zhengwei Li

Wei Zheng

Jie Shen

Hailiang Chen

Wenjie Sun

Yingchun Liu

Wei Pan

Haixia Zhao

Jiangpeng Liao

Deheng Sun

Zhongwen Yang

Yang Yue

Qiang Xiao

Jing Yang

Wen Zhou

Lili Fan

XiaWei Wei

Ning Jiang

Li'e Li

Nengyang Shi

Hua Tian

Linlin Chen

Yanping Yu

Provided is an aldehyde binder, specifically, disclosed is a compound as represented by formula (II) or a pharmaceutically acceptable salt.

Compound for use in retinal diseases

A crystal form of a pyridinylphenyl compound and a preparation method therefor. Use of the crystal form in the preparation of a medicament of treating related diseases is also comprised.

Crystal form of pyridinylphenyl compound and preparation method therefor

A novel indazole compound, a preparation method therefor, and use thereof in the preparation of drugs for treating related diseases. Specifically disclosed are a compound of formula (II) and a pharmaceutically acceptable salt thereof.

Indazole-fused cyclic compound

The present invention relates to a pyrrolopyrimidine compound used as a JAK inhibitor, and the use thereof in the preparation of a drug for treating a JAK1- and/or JAK2-associated disease, and in specifically relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Pyrrolopyrimidine compound and use thereof

Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.

Estrogen receptor antagonist

Disclosed are a [1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and an application thereof in preparing a drug for treating a disease related to JAK1 or/and TYK2. Specifically, the present invention relates to a compound represented by formula (I), or an isomer or pharmaceutically acceptable salt thereof. (I)

[1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and use thereof

Disclosed are a class of BTK kinase inhibitor compounds with a high activity and a high selectivity and the use thereof in the preparation of a drug for treating BTK target-related diseases. Specifically, disclosed are a compound shown as formula (I), and an isomer and a pharmaceutically acceptable salt thereof.

Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors

Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof. 

Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor

Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof. 

Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors

Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor. 

Uracil compound as c-MET/AXL inhibitor

Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor

Disclosed in the present application are a class of compounds as JAK inhibitors and use thereof in the preparation of medicaments for treating JAK and TYK2 related diseases. Specifically, a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof is disclosed.

JAK inhibitor and use thereof

Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof. 

Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors. 

Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors

Growing community of inventors

Shanghai, China

Guoping Hu